Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Chinese Patent Office
AstraZeneca
Cantor Fitzgerald
Cerilliant
Merck
Dow
Harvard Business School

Generated: April 21, 2018

DrugPatentWatch Database Preview

Fougera Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for FOUGERA PHARMS INC, and when can generic versions of FOUGERA PHARMS INC drugs launch?

FOUGERA PHARMS INC has twenty-eight approved drugs.

There are three US patents protecting FOUGERA PHARMS INC drugs.

There are forty-two patent family members on FOUGERA PHARMS INC drugs in twenty countries and twenty-one supplementary protection certificates in eleven countries.

Summary for Fougera Pharms Inc
International Patents:42
US Patents:3
Tradenames:15
Ingredients:15
NDAs:28

Drugs and US Patents for Fougera Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms Inc VEREGEN sinecatechins OINTMENT;TOPICAL 021902-001 Oct 31, 2006 RX Yes Yes 7,858,662 ➤ Try a Free Trial Y ➤ Try a Free Trial
Fougera Pharms Inc BETAMETHASONE DIPROPIONATE betamethasone dipropionate OINTMENT;TOPICAL 019141-001 Sep 4, 1984 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Fougera Pharms Inc FLUOCINOLONE ACETONIDE fluocinolone acetonide OINTMENT;TOPICAL 088168-001 Dec 16, 1982 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Fougera Pharms Inc FLUOCINONIDE fluocinonide GEL;TOPICAL 072933-001 Dec 30, 1994 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Fougera Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,968,973 Method for treating hyperplasia ➤ Try a Free Trial
6,197,808 Methods for treating hyperplasia ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Fougera Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00581 Netherlands ➤ Try a Free Trial PRODUCT NAME: DROOG EXTRACT VAN GROENE THEE; NAT. REGISTRATION NO/DATE: RVG 110904 20120917; FIRST REGISTRATION: 73486.00.00 20090831
C0077 France ➤ Try a Free Trial PRODUCT NAME: EXTRAIT SEC RAFFINE DE FEUILLE DE THE VERT (CAMELLIA SINENSIS) (L.) O. KUNTZE QUANTIFIE EN GALLATE D'(-)-EPIGALLOCATECHINE; NAT. REGISTRATION NO/DATE: NL 41799 20120625; FIRST REGISTRATION: 73486.00.00 20090831
401 Luxembourg ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
1304992/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Citi
Teva
US Army
McKesson
Deloitte
Chinese Patent Office
Federal Trade Commission
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.